???global.info.a_carregar???
Juan José Lasarte. Graduated in Biological Sciences from the University of Navarra in 1988, defended his Doctoral Thesis in Science in December 1992. After a post-doc period at the Pasteur Institute in Paris became part of the staff of the Center for Applied Medical Research (CIMA). He is professor of Immunology at the University of Navarra and the Director of the Immunology and Immunotherapy program at CIMA. His scientific activity has been focused on the mechanisms of induction of cellular and humoral immune responses and the development of antiviral and antitumor vaccines using peptides, recombinant proteins, viral vectors or adoptive T cell based therapies. He has participated in the publication of over 130 articles in international journals and has been co-inventor on 17 patents. Some of these patents are in clinical phases for the treatment of various pathologies.
Read full resume ↓
Identification

Personal identification

Full name
Juan José Lasarte

Citation names

  • Lasarte, Juan
  • Lasarte Juan José

Author identifiers

Ciência ID
C514-9B90-2E70
ORCID iD
0000-0003-1641-3881

Addresses

  • Edificio CIMA, Pio XII, 55, 31008, Pamplona, Navarra, Spain (Professional)

Websites

Knowledge fields

  • Medical and Health Sciences - Basic Medicine - Immunology

Languages

Language Speaking Reading Writing Listening Peer-review
Spanish; Castilian (Mother tongue)
English Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Education
Degree Classification
1983/09/01 - 1987/06/15
Concluded
 Biology (Doktor (PhD))
Universidad de Navarra, Spain
"Inducción in vivo de linfocitos T citotóxicos mediante péptidos sintéticos: aplicación a la infección por el VIH-1," (THESIS/DISSERTATION)
Affiliation

Science

Category
Host institution 		Employer
1995/02/10 - Current Principal Investigator (Research) Fundación para la Investigación Médica Aplicada, Spain
Centro de Investigación Médica Aplicada, Spain
Projects

Grant

Designation Funders
2021 - 2023 Targeting the tumor microenvironment to improve CAR-T cell based immunotherapy in pancreatic cancer
PLEC2021-008094
 Gobierno de España
2020/01/01 - 2022/12/31 El microambiente tumoral como diana para el desarrollo de inmunoterapias CAR-T en tumores solidos
PID2019-108989RB-I00
Principal investigator
Centro de Investigación Médica Aplicada, Spain
 Gobierno de España Ministerio de Ciencia e Innovación
Ongoing
2019 - 2022 Desarrollo EStratégico de terapias CART para el tratamiento de Tumores Hematológicos y Sólidos (DESCARTHeS)
0011-1411-2019-000079
 Gobierno de Navarra
2018 - 2022 Neuronal self-renewal by antigen-specific tolerization in multiple sclerosis reinstalling the balance between inflammation and regeneration
Grant Agreement number: 779316
 European Union
2019/01/01 - 2021/12/31 Desarrollo EStratégico de terapias CART para el tratamiento de Tumores Hematológicos y Sólidos (DESCARTHeS)
0011-1411- 2019-000079
Principal investigator
Centro de Investigación Médica Aplicada, Spain
Ongoing
2018 - 2021 Plataformas automáticas de producción de células CAR T para el tratamiento de leucemia B y linfoma B (AUTOCART)
RTC-2017-6578-1
 Gobierno de España
2017 - 2019 Dual epigenetic targeting and immunotherapy to fight against cancer.
AC16/00041
 Instituto de Salud Carlos III
2014 - 2016 Red de inmunoterapia del cáncer.
SAF2014-53563
 Gobierno de España
2010 - 2014 HEPACUTE: Host and viral factors in acute hepatitis
260844
 European Union
2007 - 2010 Development of an effective RNA interference-based anti-HIV-1 therapy using an SV40-derived gene transfer vector
HIVSTOP 037301
 European Union
Outputs

Publications

Journal article
  1. Lozano T; Conde E; Martín-Otal C; Navarro F; Lasarte-Cia A; Nasrallah R; Alignani D; et al. "TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity.". Cancer letters (2021): http://europepmc.org/abstract/med/34973390.
    10.1016/j.canlet.2021.12.030
  2. Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; et al. "Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.". Emerging microbes & infections (2021): http://europepmc.org/abstract/med/34538222.
    10.1080/22221751.2021.1978823
  3. Zambom-Ferraresi F; Fernández-Irigoyen J; Lachén-Montes M; Cartas-Cejudo P; Lasarte JJ; Casares N; Fernández S; Cedeño-Veloz BA; Martínez-Velilla N. "Olfactory Characterization and Training in Older Adults: Protocol Study.". Frontiers in aging neuroscience (2021): http://europepmc.org/abstract/med/34867284.
    10.3389/fnagi.2021.757081
  4. Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; et al. "Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.". Journal for immunotherapy of cancer (2021): http://europepmc.org/abstract/med/34810235.
    10.1136/jitc-2021-003351
  5. Ester Gonzalez-Sanchez; Javier Vaquero; Maite G. Férnandez-Barrena; Juan José Lasarte; Matías A. Avila; Pablo Sarobe; María Reig; Mariona Calvo; Isabel Fabregat. "The TGF-ß Pathway: A Pharmacological Target in Hepatocellular Carcinoma?". Cancers 13 13 (2021): 3248-3248. https://doi.org/10.3390/cancers13133248.
    10.3390/cancers13133248
  6. Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K. "Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.". Frontiers in immunology (2021): http://europepmc.org/abstract/med/33859645.
    10.3389/fimmu.2021.652160
  7. Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; et al. "SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.". Journal for immunotherapy of cancer (2021): http://europepmc.org/abstract/med/33658304.
    10.1136/jitc-2020-001496
  8. Teresa Lozano; Noelia Casares; Celia Martil-Otal; Blanca Anega; Marta Gorraiz; Jonathan Parker; MARTA RUIZ EGOZCUE; et al. "Searching for Peptide Inhibitors of T Regulatory Cell Activity by Targeting Specific Domains of FOXP3 Transcription Factor". Biomedicines (2021): https://www.mdpi.com/2227-9059/9/2/197.
    10.3390/biomedicines9020197
  9. Aritz Lasarte-Cia; Teresa Lozano; David Cano; Celia Martín-Otal; Flor Navarro; Marta Gorraiz; Noelia Casares; et al. "Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma". BioMed Research International (2021): https://doi.org/10.1155/2021/8852233.
    10.1155/2021/8852233
  10. Salas-Benito D; Conde E; Tamayo-Uria I; Mancheño U; Elizalde E; Garcia-Ros D; Aramendia JM; et al. "The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes.". British journal of cancer (2021): http://europepmc.org/abstract/med/33402737.
    10.1038/s41416-020-01218-4
  11. Leyre Silva; Josune Egea; Lorea Villanueva; Marta Ruiz; Diana Llopiz; David Repáraz; Belén Aparicio; et al. "Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma". Cancers 12 11 (2020): 3397-3397. https://doi.org/10.3390/cancers12113397.
    10.3390/cancers12113397
  12. Llopiz D; Ruiz M; Silva L; Repáraz D; Aparicio B; Egea J; Lasarte JJ; et al. "Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.". Cancer letters (2020): http://europepmc.org/abstract/med/33232788.
    10.1016/j.canlet.2020.11.022
  13. Iosune Baraibar; MARTA ROMAN MORENO; María Rodríguez-Remírez; Inés López; Anna Vilalta; Elizabeth Guruceaga; Margarita Ecay; et al. "Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells". Cancers (2020): https://www.mdpi.com/2072-6694/12/11/3169.
    10.3390/cancers12113169
  14. Athie A; Marchese FP; González J; Lozano T; Raimondi I; Juvvuna PK; Abad A; et al. "Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion.". The Journal of cell biology (2020): http://europepmc.org/abstract/med/32858747.
    10.1083/jcb.201908078
  15. Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; et al. "Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.". Journal for immunotherapy of cancer (2020): http://europepmc.org/abstract/med/32581060.
    10.1136/jitc-2020-000704
  16. Galluzzi L; Vitale I; Warren S; Adjemian S; Agostinis P; Martinez AB; Chan TA; et al. "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.". Journal for immunotherapy of cancer (2020): http://europepmc.org/abstract/med/32209603.
    10.1136/jitc-2019-000337
  17. Lozano T; Chocarro S; Martin C; Lasarte-Cia A; Del Valle C; Gorraiz M; Sarrión P; et al. "Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies.". Frontiers in immunology (2019): http://europepmc.org/abstract/med/31921216.
    10.3389/fimmu.2019.02990
  18. M. Ivars; A. España; P. Alzuguren; B. Pelacho; J.J. Lasarte; M.J. López-Zabalza. "The involvement of ADAM 10 in acantholysis in mucocutaneous pemphigus vulgaris depends on the autoantibody profile of each patient". British Journal of Dermatology (2019): https://doi.org/10.1111/bjd.18382.
    10.1111/bjd.18382
  19. Diana Llopiz; Marta Ruiz; Lorea Villanueva; Tamara Iglesias; Leyre Silva; Josune Egea; Juan J. Lasarte; et al. "Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model". Cancer Immunology, Immunotherapy 68 3 (2019): 379-393. https://doi.org/10.1007/s00262-018-2283-0.
    10.1007/s00262-018-2283-0
  20. Ballesteros-Briones, M.C.; Martisova, E.; Casales, E.; Silva-Pilipich, N.; Buñuales, M.; Galindo, J.; Mancheño, U.; et al. "Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses". Molecular Therapy (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85072573592&partnerID=MN8TOARS.
    10.1016/j.ymthe.2019.09.016
  21. Pascual, M.; Mena-Varas, M.; Robles, E.; Garcia-Barchino, M.-J.; Panizo, C.; Hervas-Stubbs, S.; Alignani, D.; et al. "PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas". Blood 133 22 (2019): 2401-2412. http://www.scopus.com/inward/record.url?eid=2-s2.0-85067269851&partnerID=MN8TOARS.
    10.1182/blood.2018889931
  22. Vasquez, M.; Consuegra-Fernández, M.; Aranda, F.; Jimenez, A.; Tenesaca, S.; Fernandez-Sendin, M.; Gomar, C.; et al. "Treatment of experimental autoimmune encephalomyelitis by sustained delivery of low-dose IFN-a". Journal of Immunology 203 3 (2019): 696-704. http://www.scopus.com/inward/record.url?eid=2-s2.0-85069554910&partnerID=MN8TOARS.
    10.4049/jimmunol.1801462
  23. Segovia, C.; San José-Enériz, E.; Munera-Maravilla, E.; Martínez-Fernández, M.; Garate, L.; Miranda, E.; Vilas-Zornoza, A.; et al. "Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression". Nature Medicine (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85068562974&partnerID=MN8TOARS.
    10.1038/s41591-019-0499-y
  24. Vivas, I.; Iribarren, K.; Lozano, T.; Cano, D.; Lasarte-Cia, A.; Chocarro, S.; Gorraiz, M.; et al. "Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma". Journal of Vascular and Interventional Radiology 30 7 (2019): 1098-1105. http://www.scopus.com/inward/record.url?eid=2-s2.0-85065516082&partnerID=MN8TOARS.
    10.1016/j.jvir.2019.02.023
  25. Setiawan, M.F.; Rudan, O.; Vogt, A.; Gonzalez-Carmona, M.A.; Langhans, B.; Schmidt-Wolf, R.; Garofano, F.; et al. "FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells". Anticancer research 39 10 (2019): 5369-5374. http://www.scopus.com/inward/record.url?eid=2-s2.0-85072781559&partnerID=MN8TOARS.
    10.21873/anticanres.13730
  26. Lasarte-Cia A; Lozano T; Pérez-González M; Gorraiz M; Iribarren K; Hervás-Stubbs S; Sarobe P; et al. "Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice.". Frontiers in immunology (2018): http://europepmc.org/abstract/med/29422905.
    10.3389/fimmu.2018.00068
  27. Villanueva, L.; Silva, L.; Llopiz, D.; Ruiz, M.; Iglesias, T.; Lozano, T.; Casares, N.; et al. "The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer". OncoImmunology 7 4 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85038640354&partnerID=MN8TOARS.
    10.1080/2162402X.2017.1409321
  28. Villanueva L; Silva L; Llopiz D; Ruiz M; Iglesias T; Lozano T; Casares N; et al. "The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.". Oncoimmunology (2017): http://europepmc.org/abstract/med/29632721.
    10.1080/2162402x.2017.1409321
  29. Celay J; Lozano T; Concepcion AR; Beltrán E; Rudilla F; García-Barchino MJ; Robles EF; et al. "Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.". Haematologica (2017): http://europepmc.org/abstract/med/29191842.
    10.3324/haematol.2017.175687
  30. Soldevilla MM; Hervas S; Villanueva H; Lozano T; Rabal O; Oyarzabal J; Lasarte JJ; et al. "Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).". PloS one (2017): http://europepmc.org/abstract/med/28934318.
    10.1371/journal.pone.0185169
  31. Moreno Ayala MA; Gottardo MF; Imsen M; Asad AS; Bal de Kier Joffé E; Casares N; Lasarte JJ; Seilicovich A; Candolfi M. "Therapeutic blockade of Foxp3 in experimental breast cancer models.". Breast cancer research and treatment (2017): http://europepmc.org/abstract/med/28756536.
    10.1007/s10549-017-4414-2
  32. Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; et al. "Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.". Cancer research (2017): http://europepmc.org/abstract/med/28522749.
    10.1158/0008-5472.can-17-0236
  33. Lozano T; Gorraiz M; Lasarte-Cía A; Ruiz M; Rabal O; Oyarzabal J; Hervás-Stubbs S; et al. "Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.". Oncotarget (2017): http://europepmc.org/abstract/med/29069740.
    10.18632/oncotarget.17845
  34. Consuegra-Fernández M; Martínez-Florensa M; Aranda F; de Salort J; Armiger-Borràs N; Lozano T; Casares N; et al. "Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.". Frontiers in immunology (2017): http://europepmc.org/abstract/med/28611770.
    10.3389/fimmu.2017.00594
  35. San José-Enériz E; Agirre X; Rabal O; Vilas-Zornoza A; Sanchez-Arias JA; Miranda E; Ugarte A; et al. "Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.". Nature communications (2017): http://europepmc.org/abstract/med/28548080.
    10.1038/ncomms15424
  36. Ajona D; Ortiz-Espinosa S; Moreno H; Lozano T; Pajares MJ; Agorreta J; Bértolo C; et al. "A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.". Cancer discovery (2017): http://europepmc.org/abstract/med/28288993.
    10.1158/2159-8290.cd-16-1184
  37. Takiishi T; Cook DP; Korf H; Sebastiani G; Mancarella F; Cunha JP; Wasserfall C; et al. "Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10-Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells.". (2017): http://europepmc.org/abstract/med/28108611.
    10.2337/db15-1625
  38. Fernandez-Poma, S.M.; Salas-Benito, D.; Lozano, T.; Casares, N.; Riezu-Boj, J.-I.; Mancheño, U.; Elizalde, E.; et al. "Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy". Cancer Research 77 13 (2017): 3672-3684. http://www.scopus.com/inward/record.url?eid=2-s2.0-85023776400&partnerID=MN8TOARS.
    10.1158/0008-5472.CAN-17-0236
  39. Ajona, D.; Ortiz-Espinosa, S.; Moreno, H.; Lozano, T.; Pajares, M.J.; Agorreta, J.; Bértolo, C.; et al. "A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis". Cancer Discovery 7 7 (2017): 694-703. http://www.scopus.com/inward/record.url?eid=2-s2.0-85022006257&partnerID=MN8TOARS.
    10.1158/2159-8290.CD-16-1184
  40. Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; et al. "IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.". (2016): http://europepmc.org/abstract/med/27926522.
    10.18632/oncotarget.13736
  41. Rollier CS; Verschoor EJ; Verstrepen BE; Drexhage JA; Paranhos-Baccala G; Liljeström P; Sutter G; et al. "T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.". (2016): http://europepmc.org/abstract/med/27416077.
    10.1038/gt.2016.55
  42. Lozano T; Soldevilla MM; Casares N; Villanueva H; Bendandi M; Lasarte JJ; Pastor F. "Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy.". (2016): http://europepmc.org/abstract/med/26999456.
    10.1016/j.biomaterials.2016.03.007
  43. Berraondo P; Ochoa MC; Rodriguez-Ruiz ME; Minute L; Lasarte JJ; Melero I. "Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.". (2016): http://europepmc.org/abstract/med/27308833.
    10.1158/0008-5472.can-15-3279
  44. Soldevilla MM; Villanueva H; Casares N; Lasarte JJ; Bendandi M; Inoges S; López-Díaz de Cerio A; Pastor F. "MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells.". (2016): http://europepmc.org/abstract/med/26992239.
    10.18632/oncotarget.8095
  45. Berraondo, P.; Ochoa, M.C.; Rodriguez-Ruiz, M.E.; Minute, L.; Lasarte, J.J.; Melero, I.. "Immunostimulatory monoclonal antibodies and immunomodulation: Harvesting the crop". Cancer Research 76 10 (2016): 2863-2867. http://www.scopus.com/inward/record.url?eid=2-s2.0-84971506905&partnerID=MN8TOARS.
    10.1158/0008-5472.CAN-15-3279
  46. Llopiz, D.; Aranda, F.; Díaz-Valdés, N.; Ruiz, M.; Infante, S.; Belsúe, V.; Lasarte, J.J.; Sarobe, P.. "Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination". OncoImmunology 5 2 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-84959420669&partnerID=MN8TOARS.
    10.1080/2162402X.2015.1075113
  47. Latasa C; Echeverz M; García B; Gil C; García-Ona E; Burgui S; Casares N; et al. "Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine.". (2016): http://europepmc.org/abstract/med/27537839.
    10.1371/journal.pone.0161216
  48. García de la Garza R; Sarobe P; Merino J; Lasarte JJ; D'Avola D; Belsue V; Delgado JA; et al. "Immune monitoring of immunosuppression withdrawal of liver transplant recipients.". (2015): http://europepmc.org/abstract/med/26225458.
  49. Lozano T; Villanueva L; Durántez M; Gorraiz M; Ruiz M; Belsúe V; Riezu-Boj JI; et al. "Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.". (2015): http://europepmc.org/abstract/med/26324768.
    10.4049/jimmunol.1402997
  50. Zabaleta A; Riezu-Boj JI; Larrea E; Villanueva L; Lasarte JJ; Guruceaga E; Fisicaro P; et al. "Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance.". (2015): http://europepmc.org/abstract/med/26447929.
    10.1002/jmv.24399
  51. San Miguel JF; Paiva B; Lasarte JJ. "Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.". (2015): http://europepmc.org/abstract/med/26373276.
    10.1016/j.ccell.2015.08.009
  52. Melero I; Lasarte JJ. "Genetic basis for clinical response to CTLA-4 blockade.". (2015): http://europepmc.org/abstract/med/25693025.
    10.1056/NEJMc1415938#SA1
  53. García de la Garza, R.; Sarobe, P.; Merino, J.; Lasarte, J.J.; D'Avola, D.; Belsue, V.; Delgado, J.A.; et al. "Immune monitoring of immunosuppression withdrawal of liver transplant recipients". Transplant Immunology 33 2 (2015): 110-116. http://www.scopus.com/inward/record.url?eid=2-s2.0-84943661711&partnerID=MN8TOARS.
    10.1016/j.trim.2015.07.006
  54. Matsoukas MT; Aranguren-Ibáñez Á; Lozano T; Nunes V; Lasarte JJ; Pardo L; Pérez-Riba M. "Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners.". (2015): http://europepmc.org/abstract/med/26106221.
    10.1126/scisignal.2005918
  55. Zabaleta A; D'Avola D; Echeverria I; Llopiz D; Silva L; Villanueva L; Riezu-Boj JI; et al. "Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.". (2015): http://europepmc.org/abstract/med/26029717.
    10.1038/mtm.2015.6
  56. Melero, I.; Lasarte, J.J.. "Genetic basis for clinical response to CTLA-4 blockade". New England Journal of Medicine 372 8 (2014): 783-783. http://www.scopus.com/inward/record.url?eid=2-s2.0-84923067538&partnerID=MN8TOARS.
    10.1056/NEJMc1415938
  57. Llopiz D; Huarte E; Ruiz M; Bezunartea J; Belsúe V; Zabaleta A; Lasarte JJ; et al. "Helper cell-independent antitumor activity of potent CD8(+) T cell epitope peptide vaccines is dependent upon CD40L.". (2013): http://europepmc.org/abstract/med/24498563.
    10.4161/onci.27009
  58. de la Garza RG; Sarobe P; Merino J; Lasarte JJ; D'Avola D; Belsue V; Delgado JA; et al. "Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance.". (2013): http://europepmc.org/abstract/med/23784747.
    10.1002/lt.23686
  59. Sangro B; Gomez-Martin C; de la Mata M; Iñarrairaegui M; Garralda E; Barrera P; Riezu-Boj JI; et al. "A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.". (2013): http://europepmc.org/abstract/med/23466307.
    10.1016/j.jhep.2013.02.022
  60. Lozano T; Casares N; Lasarte JJ. "Searching for the Achilles Heel of FOXP3.". (2013): http://europepmc.org/abstract/med/24350059.
    10.3389/fonc.2013.00294
  61. Arribillaga L; Durantez M; Lozano T; Rudilla F; Rehberger F; Casares N; Villanueva L; et al. "A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo.". (2013): http://europepmc.org/abstract/med/24093105.
    10.1155/2013/864720
  62. Corrales L; Ajona D; Rafail S; Lasarte JJ; Riezu-Boj JI; Lambris JD; Rouzaut A; et al. "Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.". (2012): http://europepmc.org/abstract/med/23028051.
    10.4049/jimmunol.1201654
  63. Mansilla C; Berraondo P; Durantez M; Martínez M; Casares N; Arribillaga L; Rudilla F; et al. "Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.". (2012): http://europepmc.org/abstract/med/21898393.
    10.1002/ijc.26412
  64. Rudilla F; Fayolle C; Casares N; Durantez M; Arribillaga L; Lozano T; Villanueva L; et al. "Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses.". (2012): http://europepmc.org/abstract/med/22387222.
    10.1016/j.vaccine.2012.02.052
  65. San Román B; De Andrés X; Muñoz PM; Obregón P; Asensio AC; Garrido V; Mansilla C; et al. "The extradomain A of fibronectin (EDA) combined with poly(I:C) enhances the immune response to HIV-1 p24 protein and the protection against recombinant Listeria monocytogenes-Gag infection in the mouse model.". (2012): http://europepmc.org/abstract/med/22326778.
    10.1016/j.vaccine.2012.01.081
  66. Benitez-Ribas, D.; Borràs, F.E.; Del Val, M.; Lasarte, J.J.; Marañón, C.; Martín-Gayo, E.; Sarobe, P.; Toribio, M.L.; Montoya, M.. "Dendritic cells: Nearly 40 years later". Inmunologia 31 2 (2012): 49-57. http://www.scopus.com/inward/record.url?eid=2-s2.0-84866311990&partnerID=MN8TOARS.
    10.1016/j.inmuno.2012.03.002
  67. Román BS; Garrido V; Muñoz PM; Arribillaga L; García B; De Andrés X; Zabaleta V; et al. "The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice.". (2012): http://europepmc.org/abstract/med/22515195.
    10.1186/1297-9716-43-31
  68. Camacho AI; Da Costa Martins R; Tamayo I; de Souza J; Lasarte JJ; Mansilla C; Esparza I; Irache JM; Gamazo C. "Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators.". (2011): http://europepmc.org/abstract/med/21651945.
    10.1016/j.vaccine.2011.05.072
  69. Echeverria I; Pereboev A; Silva L; Zabaleta A; Riezu-Boj JI; Bes M; Cubero M; et al. "Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.". (2011): http://europepmc.org/abstract/med/21452282.
    10.1002/hep.24325
  70. Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; et al. "Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.". (2011): http://europepmc.org/abstract/med/21402711.
    10.1158/0008-5472.CAN-10-3259
  71. Ma Y; Aymeric L; Locher C; Mattarollo SR; Delahaye NF; Pereira P; Boucontet L; et al. "Contribution of IL-17?producing ?? T cells to the efficacy of anticancer chemotherapy.". (2011): http://europepmc.org/abstract/PMC/PMC3135341.
  72. Arribillaga L; Dotor J; Basagoiti M; Riezu-Boj JI; Borrás-Cuesta F; Lasarte JJ; Sarobe P; Cornet ME; Feijoó E. "Therapeutic effect of a peptide inhibitor of TGF-ß on pulmonary fibrosis.". (2011): http://europepmc.org/abstract/med/21185199.
    10.1016/j.cyto.2010.11.019
  73. Riezu-Boj JI; Larrea E; Aldabe R; Guembe L; Casares N; Galeano E; Echeverria I; et al. "Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection.". (2011): http://europepmc.org/abstract/med/21129807.
    10.1016/j.jhep.2010.07.014
  74. Ma Y; Aymeric L; Locher C; Mattarollo SR; Delahaye NF; Pereira P; Boucontet L; et al. "Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.". (2011): http://europepmc.org/abstract/med/21383056.
    10.1084/jem.20100269
  75. Díaz-Valdés N; Manterola L; Belsúe V; Riezu-Boj JI; Larrea E; Echeverria I; Llópiz D; et al. "Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10.". (2011): http://europepmc.org/abstract/med/21154952.
    10.1002/hep.23980
  76. Lozano, C.; Aspiroz, C.; Lasarte, J.J.; Gómez-Sanz, E.; Zarazaga, M.; Torres, C.. "Dynamic of nasal colonization by methicillin-resistant Staphylococcus aureus ST398 and ST1 after mupirocin treatment in a family in close contact with pigs". Comparative Immunology, Microbiology and Infectious Diseases 34 1 (2011): http://www.scopus.com/inward/record.url?eid=2-s2.0-79551637778&partnerID=MN8TOARS.
    10.1016/j.cimid.2010.06.006
  77. Ma, Y.; Aymeric, L.; Locher, C.; Mattarollo, S.R.; Delahaye, N.F.; Pereira, P.; Boucontet, L.; et al. "Correction: Contribution of IL-17-producing ¿d T cells to the efficacy of anticancer chemotherapy". Journal of Experimental Medicine 208 4 (2011): 869-869. http://www.scopus.com/inward/record.url?eid=2-s2.0-79955737394&partnerID=MN8TOARS.
    10.1084/jem.201002692084c
  78. Casares N; Rudilla F; Arribillaga L; Llopiz D; Riezu-Boj JI; Lozano T; López-Sagaseta J; et al. "A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice.". (2010): http://europepmc.org/abstract/med/20870946.
    10.4049/jimmunol.1001114
  79. Durantez M; Fayolle C; Casares N; Belsue V; Riezu-Boj JI; Sarobe P; Prieto J; et al. "Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis.". (2010): http://europepmc.org/abstract/med/20817012.
    10.1016/j.vaccine.2010.08.070
  80. Tamayo I; Irache JM; Mansilla C; Ochoa-Repáraz J; Lasarte JJ; Gamazo C. "Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.". (2010): http://europepmc.org/abstract/med/20631332.
    10.1128/CVI.00164-10
  81. Ochoa-Callejero L; Otano I; Vales A; Olagüe C; Sarobe P; Lasarte JJ; Prieto J; Menne S; González-Aseguinolaza G. "Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice.". (2010): http://europepmc.org/abstract/med/20665977.
    10.1016/j.vaccine.2010.05.043
  82. Farran I; McCarthy-Suárez I; Río-Manterola F; Mansilla C; Lasarte JJ; Mingo-Castel AM. "The vaccine adjuvant extra domain A from fibronectin retains its proinflammatory properties when expressed in tobacco chloroplasts.". (2010): http://europepmc.org/abstract/med/20108000.
    10.1007/s00425-010-1102-4
  83. Aspiroz C; Lozano C; Vindel A; Lasarte JJ; Zarazaga M; Torres C. "Skin lesion caused by ST398 and ST1 MRSA, Spain.". (2010): http://europepmc.org/abstract/med/20031071.
    10.3201/eid1601.090694
  84. Llopiz D; Dotor J; Casares N; Bezunartea J; Díaz-Valdés N; Ruiz M; Aranda F; et al. "Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.". (2009): http://europepmc.org/abstract/med/19530254.
    10.1002/ijc.24656
  85. Mansilla C; Gorraiz M; Martinez M; Casares N; Arribillaga L; Rudilla F; Echeverria I; et al. "Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein.". (2009): http://europepmc.org/abstract/med/19596480.
    10.1016/j.jhep.2009.06.005
  86. Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P. "Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.". (2009): http://europepmc.org/abstract/med/19144076.
    10.1111/j.1365-3083.2008.02202.x
  87. Hermida N; López B; González A; Dotor J; Lasarte JJ; Sarobe P; Borrás-Cuesta F; Díez J. "A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats.". (2009): http://europepmc.org/abstract/med/19019833.
    10.1093/cvr/cvn315
  88. Echeverría I; Zabaleta A; Silva L; Díaz-Valdés N; Riezu-Boj JI; Lasarte JJ; Borrás-Cuesta F; et al. "Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C).". (2008): http://europepmc.org/abstract/med/18637068.
    10.1111/j.1365-2893.2008.01020.x
  89. Gil-Guerrero L; Dotor J; Huibregtse IL; Casares N; López-Vázquez AB; Rudilla F; Riezu-Boj JI; et al. "In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1.". (2008): http://europepmc.org/abstract/med/18566377.
    10.4049/jimmunol.181.1.126
  90. El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H. "Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.". (2008): http://europepmc.org/abstract/med/18076128.
    10.1002/jgm.1144
  91. Zabaleta A; Llopiz D; Arribillaga L; Silva L; Riezu-Boj JI; Lasarte JJ; Borrás-Cuesta F; Prieto J; Sarobe P. "Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.". (2008): http://europepmc.org/abstract/med/17923840.
    10.1038/sj.mt.6300333
  92. Llopiz D; Dotor J; Zabaleta A; Lasarte JJ; Prieto J; Borrás-Cuesta F; Sarobe P. "Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.". (2008): http://europepmc.org/abstract/med/17564702.
    10.1007/s00262-007-0346-8
  93. Gil-Guerrero, L.; Dotor, J.; Huibregtse, I.L.; Casares, N.; López-Vázquez, A.B.; Rudilla, F.; Riezu-Boj, J.I.; et al. "In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-ß1". Journal of Immunology 181 1 (2008): 126-135. http://www.scopus.com/inward/record.url?eid=2-s2.0-47949104587&partnerID=MN8TOARS.
  94. Zabala M; Lasarte JJ; Perret C; Sola J; Berraondo P; Alfaro M; Larrea E; Prieto J; Kramer MG. "Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer.". (2007): http://europepmc.org/abstract/med/17935823.
    10.1016/j.jhep.2007.07.025
  95. Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E. "Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.". (2007): http://europepmc.org/abstract/med/17940994.
    10.1002/path.2214
  96. Arina A; Murillo O; Hervás-Stubbs S; Azpilikueta A; Dubrot J; Tirapu I; Huarte E; et al. "The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.". (2007): http://europepmc.org/abstract/med/17520674.
    10.1002/ijc.22795
  97. Dotor J; López-Vázquez AB; Lasarte JJ; Sarobe P; García-Granero M; Riezu-Boj JI; Martínez A; et al. "Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library.". (2007): http://europepmc.org/abstract/med/17804251.
    10.1016/j.cyto.2007.06.004
  98. Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; et al. "Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.". (2007): http://europepmc.org/abstract/med/17275104.
    10.1016/j.antiviral.2007.01.001
  99. Larrea E; Riezu-Boj JI; Gil-Guerrero L; Casares N; Aldabe R; Sarobe P; Civeira MP; et al. "Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.". (2007): http://europepmc.org/abstract/med/17229698.
    10.1128/JVI.02248-06
  100. Rollier CS; Paranhos-Baccala G; Verschoor EJ; Verstrepen BE; Drexhage JA; Fagrouch Z; Berland JL; et al. "Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity.". (2007): http://europepmc.org/abstract/med/17326154.
    10.1002/hep.21573
  101. Ruiz M; Llopiz D; Zabaleta A; Lasarte JJ; Borrás-Cuesta F; Sarobe P. "Engineered promiscuous T helper peptides for the induction of immune responses.". (2007): http://europepmc.org/abstract/med/17157914.
    10.1016/j.molimm.2006.11.001
  102. Lasarte JJ; Casares N; Gorraiz M; Hervás-Stubbs S; Arribillaga L; Mansilla C; Durantez M; et al. "The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo.". (2007): http://europepmc.org/abstract/med/17202335.
    10.4049/jimmunol.178.2.748
  103. Casares, N.; Gil-Guerrero, L.; Melero, I.; Dubrot, J.; Lasarte, J.J.. "The many faces of regulatory T cells". Inmunologia 26 1 (2007): 29-41. http://www.scopus.com/inward/record.url?eid=2-s2.0-34347373935&partnerID=MN8TOARS.
  104. Mintegi S; Fernández A; Alustiza J; Canduela V; Mongil I; Caubet I; Clerigué N; et al. "Emergency visits for childhood poisoning: a 2-year prospective multicenter survey in Spain.". (2006): http://europepmc.org/abstract/med/16714960.
    10.1097/01.pec.0000215651.50008.1b
  105. Sarobe P; Lasarte JJ; García N; Civeira MP; Borrás-Cuesta F; Prieto J. "Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins.". (2006): http://europepmc.org/abstract/med/16364082.
    10.1111/j.1365-2893.2005.00653.x
  106. Alfaro, C.; Murillo, O.; Tirapu, I.; Azpilicueta, A.; Huarte, E.; Arina, A.; Arribillaga, L.; et al. "The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases,El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones virales crónicas". Anales del Sistema Sanitario de Navarra 29 1 (2006): 77-96. http://www.scopus.com/inward/record.url?eid=2-s2.0-33646686590&partnerID=MN8TOARS.
  107. Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; et al. "[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases]". (2006): http://europepmc.org/abstract/med/16670731.
    10.4321/S1137-66272006000100007
  108. Ezquerro, I.-J.; Lasarte, J.-J.; Dotor, J.; Castilla-Cortázar, I.; Bustos, M.; Peñuelas, I.; Blanco, G.; et al. "Erratum: A synthetic peptide from transforming growth factor ß type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury (Cytokine (2003) 22 (12-20) DOI: 10.1016/S1043-4666(03)00101-7)". Cytokine 33 2 (2006): 119-119. http://www.scopus.com/inward/record.url?eid=2-s2.0-33644988564&partnerID=MN8TOARS.
    10.1016/j.cyto.2005.11.001
  109. Santiago B; Gutierrez-Cañas I; Dotor J; Palao G; Lasarte JJ; Ruiz J; Prieto J; Borrás-Cuesta F; Pablos JL. "Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis.". (2005): http://europepmc.org/abstract/med/16117784.
    10.1111/j.0022-202X.2005.23859.x
  110. Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; et al. "Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.". (2005): http://europepmc.org/abstract/med/16088843.
    10.1086/432517
  111. Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; et al. "Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.". (2005): http://europepmc.org/abstract/med/15855007.
    10.1016/j.vaccine.2005.02.003
  112. López B; González A; Lasarte JJ; Sarobe P; Borrás F; Díaz A; Barba J; et al. "Is plasma cardiotrophin-1 a marker of hypertensive heart disease?". (2005): http://europepmc.org/abstract/med/15716706.
    10.1097/01.hjh.0000160221.09468.d3
  113. Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; et al. "Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.". (2005): http://europepmc.org/abstract/med/15661387.
    10.1016/j.vaccine.2004.09.009
  114. Sarobe P; Huarte E; Lasarte JJ; Borrás-Cuesta F. "Carcinoembryonic antigen as a target to induce anti-tumor immune responses.". (2004): http://europepmc.org/abstract/med/15320719.
    10.2174/1568009043332916
  115. Ruiz M; Kobayashi H; Lasarte JJ; Prieto J; Borrás-Cuesta F; Celis E; Sarobe P. "Identification and characterization of a T-helper peptide from carcinoembryonic antigen.". (2004): http://europepmc.org/abstract/med/15102695.
    10.1158/1078-0432.CCR-03-0476
  116. Sarobe, P.; Lasarte, J.J.; Casares, N.; Onji, M.. "Erratum: Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins (Clinical and Experimental Immunology (2002) 76 (5062-5070))". Clinical and Experimental Immunology 138 1 (2004): 193-193. http://www.scopus.com/inward/record.url?eid=2-s2.0-4644351193&partnerID=MN8TOARS.
    10.1111/j.1365-2249.2004.02631.x
  117. Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ. "CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.". (2003): http://europepmc.org/abstract/med/14634104.
    10.4049/jimmunol.171.11.5931
  118. Sarobe P; Lasarte JJ; Zabaleta A; Arribillaga L; Arina A; Melero I; Borrás-Cuesta F; Prieto J. "Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.". (2003): http://europepmc.org/abstract/med/14512536.
    10.1128/JVI.77.20.10862-10871.2003
  119. Portal-Núñez S; González-Navarro CJ; García-Delgado M; Vizmanos JL; Lasarte JJ; Borrás-Cuesta F. "Peptide inhibitors of hepatitis C virus NS3 protease.". (2003): http://europepmc.org/abstract/med/14694985.
  120. Bustos M; Beraza N; Lasarte JJ; Baixeras E; Alzuguren P; Bordet T; Prieto J. "Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats.". (2003): http://europepmc.org/abstract/med/12851883.
    10.1016/S0016-5085(03)00698-X
  121. López-Díaz de Cerio A; Lasarte JJ; Casares N; Sarobe P; Ruiz M; Prieto J; Borrás-Cuesta F. "Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses.". (2003): http://europepmc.org/abstract/med/12750353.
    10.1093/intimm/dxg071
  122. Ezquerro IJ; Lasarte JJ; Dotor J; Castilla-Cortázar I; Bustos M; Peñuelas I; Blanco G; et al. "A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury.". (2003): http://europepmc.org/abstract/med/12946101.
    10.1016/S1043-4666(03)00101-7
  123. Lasarte JJ; Sarobe P; Boya P; Casares N; Arribillaga L; de Cerio AL; Gorraiz M; Borrás-Cuesta F; Prieto J. "A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage.". (2003): http://europepmc.org/abstract/med/12540797.
    10.1053/jhep.2003.50073
  124. Portal-Núñez, S.; González-Navarro, C.J.; García-Delgado, M.; Vizmanos, J.L.; Lasarte, J.J.; Borrás-Cuesta, F.. "Peptide inhibitors of hepatitis C virus NS3 protease". Antiviral Chemistry and Chemotherapy 14 5 (2003): 225-233. http://www.scopus.com/inward/record.url?eid=2-s2.0-0345098563&partnerID=MN8TOARS.
    10.1177/095632020301400501
  125. Casares, N.; Arribillaga, L.; Sarobe, P.; Dotor, J.; De Cerio, A.L.-D.; Melero, I.; Prieto, J.; Borrás-Cuesta, F.; Lasarte, J.J.. "CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-¿-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination". Journal of Immunology 171 11 (2003): 5931-5939. http://www.scopus.com/inward/record.url?eid=2-s2.0-0344153890&partnerID=MN8TOARS.
  126. Arribillaga L; de Cerio AL; Sarobe P; Casares N; Gorraiz M; Vales A; Bruna-Romero O; et al. "Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.". (2002): http://europepmc.org/abstract/med/12450695.
    10.1016/S0264-410X(02)00456-5
  127. Martino VS; López P; Martinez Irujo JJ; Sanromán M; Cuevas MT; Santiago E; Lasarte JJ; et al. "Inhibitory effect against polymerase and ribonuclease activities of HIV-reverse transcriptase of the aqueous leaf extract of Terminalia triflora.". (2002): http://europepmc.org/abstract/med/12458488.
    10.1002/ptr.1065
  128. Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; et al. "Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.". (2002): http://europepmc.org/abstract/med/12374692.
  129. Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; et al. "Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.". (2002): http://europepmc.org/abstract/med/12114438.
  130. Sarobe P; Lasarte JJ; Casares N; López-Díaz de Cerio A; Baixeras E; Labarga P; García N; Borrás-Cuesta F; Prieto J. "Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins.". (2002): http://europepmc.org/abstract/med/11967322.
    10.1128/JVI.76.10.5062-5070.2002
  131. Huarte E; Sarobe P; Lasarte JJ; Brem G; Weiss EH; Prieto J; Borrás-Cuesta F. "Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen.". (2002): http://europepmc.org/abstract/med/11774244.
    10.1002/ijc.1579
  132. Huarte, E.; Sarobe, P.; Lu, J.; Casares, N.; Lasarte, J.J.; Dotor, J.; Ruiz, M.; et al. "Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements". Clinical Cancer Research 8 7 (2002): 2336-2344. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035992407&partnerID=MN8TOARS.
  133. Kobayashi, H.; Omiya, R.; Ruiz, M.; Huarte, E.; Sarobe, P.; Lasarte, J.J.; Herraiz, M.; et al. "Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen". Clinical Cancer Research 8 10 (2002): 3219-3225. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036793872&partnerID=MN8TOARS.
  134. Huarte, E.; Sarobe, P.; Lasarte, J.J.; Brem, G.; Weiss, E.H.; Prieto, J.; Borrás-Cuesta, F.. "Sun exposure and interaction with family history in risk of Melanoma, Queensland, Australia". International Journal of Cancer 97 1 (2002): 90-95. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036132045&partnerID=MN8TOARS.
    10.1002/ijc.1563
  135. García-Navarro R; Blanco-Urgoiti B; Berraondo P; Sánchez de la Rosa R; Vales A; Hervás-Stubbs S; Lasarte JJ; et al. "Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12.". (2001): http://europepmc.org/abstract/med/11533170.
    10.1128/JVI.75.19.9068-9076.2001
  136. Hervás-Stubbs S; Lasarte JJ; Sarobe P; Vivas I; Condreay L; Cullen JM; Prieto J; Borrás-Cuesta F. "T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine.". (2001): http://europepmc.org/abstract/med/11495027.
    10.1016/S0168-8278(01)00063-0
  137. Casares N; Lasarte JJ; de Cerio AL; Sarobe P; Ruiz M; Melero I; Prieto J; Borrás-Cuesta F. "Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity.". (2001): http://europepmc.org/abstract/med/11385623.
    10.1002/1521-4141(200106)31:6<1780::AID-IMMU1780>3.0.CO;2-I
  138. Sarobe P; Huarte E; Lasarte JJ; López-Díaz de Cerio A; García N; Borrás-Cuesta F; Prieto J. "Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes.". (2001): http://europepmc.org/abstract/med/11281563.
    10.1016/S0168-8278(00)00018-0
  139. Borrás-Cuesta F; Golvano J; García-Granero M; Sarobe P; Riezu-Boj J; Huarte E; Lasarte J. "Specific and general HLA-DR binding motifs: comparison of algorithms.". (2000): http://europepmc.org/abstract/med/10689116.
    10.1016/S0198-8859(99)00153-6
  140. Lópex-Días de Cerio AL; Casares N; Lasarte JJ; Sarobe P; Pérez-Mediavilla LA; Ruiz M; Prieto J; Borrás-Cuesta F. "T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides.". (1999): http://europepmc.org/abstract/med/10590268.
    10.1093/intimm/11.12.2025
  141. Lasarte JJ; Corrales FJ; Casares N; López-Díaz de Cerio A; Qian C; Xie X; Borrás-Cuesta F; Prieto J. "Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide.". (1999): http://europepmc.org/abstract/med/10228002.
  142. Hnatyszyn O; Broussalis A; Herrera G; Muschietti L; Coussio J; Martino V; Ferraro G; et al. "Argentine plant extracts active against polymerase and ribonuclease H activities of HIV-1 reverse transcriptase.". (1999): http://europepmc.org/abstract/med/10353158.
    10.1002/(SICI)1099-1573(199905)13:3<206::AID-PTR409>3.0.CO;2-D
  143. Merino I; Monge A; Font M; Martínez de Irujo JJ; Alberdi E; Santiago E; Prieto I; et al. "Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles.". (1999): http://europepmc.org/abstract/med/10384720.
    10.1016/S0014-827X(99)00035-X
  144. Mazzolini G; Qian C; Xie X; Sun Y; Lasarte JJ; Drozdzik M; Prieto J. "Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.". (1999): http://europepmc.org/abstract/med/10608348.
    10.1038/sj.cgt.7700072
  145. Lasarte, J.J.; Corrales, F.J.; Casares, N.; López-Díaz De Cerio, A.; Qian, C.; Xie, X.; Borrás-Cuesta, F.; Prieto, J.. "Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: The role of nitric oxide". Journal of Immunology 162 9 (1999): 5270-5277. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033136294&partnerID=MN8TOARS.
  146. Hervás-Stubbs, S.; Rodríguez, M.; Lasarte, J.J.; Riezu, J.I.; Berasain, C.; Prieto, J.; Borrás-Cuesta, F.. "Synthetic peptides for the induction of a humoral and cellular immune response against the hepatitis B virus and the serotype of hepatitis C virus,Peptidos sinteticos para la induccion de una respuesta inmune humoral y celular contra el virus de la hepatitis B y el tipaje del virus de la hepatitis C". Anales del Sistema Sanitario de Navarra 22 SUPPL. 3 (1999): 93-102. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033436411&partnerID=MN8TOARS.
  147. López-Díaz De Cerio, A.; Casares, N.; Lasarte, J.J.; Sarobe, P.; Pérez-Mediavilla, L.A.; Ruiz, M.; Prieto, J.; Borrás-Cuesta, F.. "T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides". International Immunology 11 12 (1999): 2025-2033. http://www.scopus.com/inward/record.url?eid=2-s2.0-0343484313&partnerID=MN8TOARS.
  148. Drozdzik M; Qian C; Lasarte JJ; Bilbao R; Prieto J. "Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).". (1998): http://europepmc.org/abstract/med/10023441.
    10.1038/sj.gt.3300763
  149. Lasarte JJ; García-Granero M; López A; Casares N; García N; Civeira MP; Borrás-Cuesta F; Prieto J. "Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.". (1998): http://europepmc.org/abstract/med/9731578.
    10.1002/hep.510280332
  150. Xie ZC; Riezu-Boj JI; Lasarte JJ; Guillen J; Su JH; Civeira MP; Prieto J. "Transmission of hepatitis C virus infection to tree shrews.". (1998): http://europepmc.org/abstract/med/9601519.
    10.1006/viro.1998.9127
  151. Lasarte, J.J.; Bruna-Romero, O.; Ruiz, J.; Quian, C.; Borras, F.; Prieto, J.. "Defective recombinant adenoviruses as a tool to induce anti-HCV immune responses". Biotecnologia Aplicada 15 3 (1998): 195-195. http://www.scopus.com/inward/record.url?eid=2-s2.0-0031755694&partnerID=MN8TOARS.
  152. Gavier B; Martínez-González MA; Riezu-Boj JI; Lasarte JJ; Garcia N; Civeira MP; Prieto J. "Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C.". (1997): http://europepmc.org/abstract/med/9352868.
  153. Hervás-Stubbs S; Lasarte JJ; Sarobe P; Prieto J; Cullen J; Roggendorf M; Borrás-Cuesta F. "Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection.". (1997): http://europepmc.org/abstract/med/9365049.
    10.1016/S0168-8278(97)80090-6
  154. Monge A; Alvarez E; San Martín C; Nadal E; Ruiz I; Font M; Martínez-Irujo JJ; et al. "Synthesis and evaluation of new Reissert analogs as HIV-1 RT inhibitors. 2. Benzo[f]quinoline and pyridine derivatives.". (1997): http://europepmc.org/abstract/med/9197980.
  155. Font M; Monge A; Alvarez E; Cuartero A; Losa MJ; Fidalgo MJ; SanMartín C; et al. "Synthesis and evaluation of new Reissert analogs as HIV-1 reverse transcriptase inhibitors. 1. Quinoline and quinoxaline derivatives.". (1997): http://europepmc.org/abstract/med/9197981.
  156. Bruña-Romero O; Lasarte JJ; Wilkinson G; Grace K; Clarke B; Borrás-Cuesta F; Prieto J. "Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus.". (1997): http://europepmc.org/abstract/med/9021966.
    10.1002/hep.510250236
  157. Bruña-Romero, O.; Lasarte, J.J.; Wilkinson, G.; Grace, K.; Clarke, B.; Borrás-Cuesta, F.; Prieto, J.. "Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus". Hepatology 25 2 (1997): 470-477. http://www.scopus.com/inward/record.url?eid=2-s2.0-0031015971&partnerID=MN8TOARS.
    10.1053/jhep.1997.v25.pm0009021966
  158. Gavier, B.; Martinez-Gonzalez, M.-A.; Riezu-Boj, J.-I.; Lasarte, J.-J.; Garcia, N.; Civeira, M.-P.; Prieto, J.. "Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C". Gastroenterology 113 5 (1997): 1647-1653. http://www.scopus.com/inward/record.url?eid=2-s2.0-0030832591&partnerID=MN8TOARS.
    10.1053/gast.1997.v113.pm9352868
  159. Monge, A.; Alvarez, E.; San Martín, C.; Nadal, E.; Ruiz, I.; Font, M.; Martínez-Irujo, J.J.; et al. "Synthesis and evaluation of new Reissert analogs as HIV-1 RT inhibitors. 2. Benzo[f]quinoline and pyridine derivatives". Drug Design and Discovery 14 4 (1997): 291-303. http://www.scopus.com/inward/record.url?eid=2-s2.0-8244257358&partnerID=MN8TOARS.
  160. Font, M.; Monge, A.; Alvarez, E.; Cuartero, A.; Losa, M.-J.; Fidalgo, M.-J.; Sanmartín, C.; et al. "Synthesis and evaluation of new Reissert analogs as HIV-1 reverse transcriptase inhibitors. 1. Quinoline and quinoxaline derivatives". Drug Design and Discovery 14 4 (1997): 305-332. http://www.scopus.com/inward/record.url?eid=2-s2.0-8244230512&partnerID=MN8TOARS.
  161. Boudet F; Lasarte JJ; Sarobe P; Borras-Cuesta F; Theze J. "Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates.". (1996): http://europepmc.org/abstract/med/8959242.
    10.1089/aid.1996.12.1671
  162. Prieto I; Lasarte JJ; Sarobe P; Golvano J; Civeira MP; Gullón A; Prieto J; Borrás-Cuesta F. "Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine.". (1996): http://europepmc.org/abstract/med/8827218.
    10.1089/aid.1996.12.1023
  163. Sarobe P; Jauregui JI; Lasarte JJ; García N; Civeira MP; Borrás-Cuesta F; Prieto J. "Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment.". (1996): http://europepmc.org/abstract/med/8836894.
    10.1016/S0168-8278(96)80320-5
  164. Janvier B; Lasarte JJ; Sarobe P; Hoebeke J; Baillou-Beaufils A; Borras-Cuesta F; Barin F. "B cell epitopes of HIV type 1 p24 capsid protein: a reassessment.". (1996): http://europepmc.org/abstract/med/8679307.
    10.1089/aid.1996.12.519
  165. Prieto I; Hervás-Stubbs S; García-Granero M; Berasain C; Riezu-Boj JI; Lasarte JJ; Sarobe P; Prieto J; Borrás-Cuesta F. "Simple strategy to induce antibodies of distinct specificity: application to the mapping of gp120 and inhibition of HIV-1 infectivity.". (1995): http://europepmc.org/abstract/med/7737288.
    10.1002/eji.1830250403
  166. Lasarte JJ; Sarobe P; Prieto J; Borrás-Cuesta F. "In vivo cytotoxic T-lymphocyte induction may take place via CD8 T helper lymphocytes.". (1995): http://europepmc.org/abstract/med/7569311.
    10.1016/0923-2494(96)80238-0
  167. Font, M.; Monge, A.; Cuartero, A.; Elorriaga, A.; Martínez-Irujo, J.J.; Alberdi, E.; Santiago, E.; et al. "Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase". European Journal of Medicinal Chemistry 30 12 (1995): 963-971. http://www.scopus.com/inward/record.url?eid=2-s2.0-0029593290&partnerID=MN8TOARS.
    10.1016/0223-5234(96)88316-4
  168. Hervás-Stubbs S; Berasain C; Golvano JJ; Lasarte JJ; Prieto I; Sarobe P; Prieto J; Borrás-Cuesta F. "Overcoming class II-linked non-responsiveness to hepatitis B vaccine.". (1994): http://europepmc.org/abstract/med/7526566.
    10.1016/0264-410X(94)90026-4
  169. Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F. "Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.". (1994): http://europepmc.org/abstract/med/8207641.
  170. Lasarte JJ; Sarobe P; Golvano J; Prieto I; Civeira MP; Gullón A; Sarin PS; Prieto J; Borrás-Cuesta F. "CD4-modified synthetic peptides containing phenylalanine inhibit HIV-1 infection in vitro.". (1994): http://europepmc.org/abstract/med/8301524.
  171. Sarobe, P.; Lasarte, J.-J.; Golvano, J.-J.; Prieto, I.; Gullón, A.; Soto, M.-J.; Labarga, P.; Prieto, J.; Borrás-Cuesta, F.. "Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr". Journal of Acquired Immune Deficiency Syndromes 7 7 (1994): 635-640. http://www.scopus.com/inward/record.url?eid=2-s2.0-0028173853&partnerID=MN8TOARS.
  172. Lasarte, J.J.; Sarobe, P.; Golvano, J.; Prieto, I.; Civeira, M.P.; Gullon, A.; Sarin, P.S.; Prieto, J.; Borras Cuesta, F.. "Cd4 modified synthetic peptides containing phenylalanine inhibit hiv 1 infection in vitro". Journal of Acquired Immune Deficiency Syndromes 7 2 (1994): http://www.scopus.com/inward/record.url?eid=2-s2.0-0028107233&partnerID=MN8TOARS.
  173. Sarobe P; Lasarte JJ; Larrea E; Golvano JJ; Prieto I; Gullón A; Prieto J; Borrás-Cuesta F. "Enhancement of peptide immunogenicity by insertion of a cathepsin B cleavage site between determinants recognized by B and T cells.". (1993): http://europepmc.org/abstract/med/7690980.
    10.1016/0923-2494(93)80102-5
  174. Lasarte JJ; Sarobe P; Gullón A; Prieto J; Borrás-Cuesta F. "Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct.". (1992): http://europepmc.org/abstract/med/1532538.
    10.1016/0008-8749(92)90140-K
  175. Borrás-Cuesta F; Golvano J; Sarobe P; Lasarte JJ; Prieto I; Szabo A; Guillaume JL; Guillet JG. "Insights on the amino acid side-chain interactions of a synthetic T-cell determinant.". (1991): http://europepmc.org/abstract/med/1719991.
    10.1016/1045-1056(91)90033-G
  176. Sarobe P; Lasarte JJ; Golvano J; Gullón A; Civeira MP; Prieto J; Borrás-Cuesta F. "Induction of antibodies against a peptide hapten does not require covalent linkage between the hapten and a class II presentable T helper peptide.". (1991): http://europepmc.org/abstract/med/1710570.
    10.1002/eji.1830210633
  177. Golvano J; Lasarte JJ; Sarobe P; Gullón A; Prieto J; Borrás-Cuesta F. "Polarity of immunogens: implications for vaccine design.". (1990): http://europepmc.org/abstract/med/1700756.
    10.1002/eji.1830201031